Insmed Incorporated (BST:IM8N)

Germany flag Germany · Delayed Price · Currency is EUR
101.00
+5.00 (5.21%)
At close: Aug 13, 2025
5.21%
Market Cap25.97B
Revenue (ttm)338.99M
Net Income (ttm)-880.74M
Shares Outn/a
EPS (ttm)-4.87
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume12
Open101.00
Previous Close96.00
Day's Range101.00 - 101.00
52-Week Range55.00 - 101.00
Betan/a
RSI89.44
Earnings DateAug 7, 2025

About Insmed

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 c... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1988
Employees 1,271
Stock Exchange Stuttgart Stock Exchange
Ticker Symbol IM8N
Full Company Profile

Financial Performance

In 2024, Insmed's revenue was $363.71 million, an increase of 19.17% compared to the previous year's $305.21 million. Losses were -$913.77 million, 21.9% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.